Name: how bacteria outsmart antibiotics
Uploaded: 2026-03-12T13:35:59.000Z
Duration: 1 min 25 s
Channel: JoVE

Staphylococcus aureus часто встречается на коже человека, но является оппортунистическим патогеном.Метициллин-резистентный Staphylococcus aureus, или MRSA, — это тип S. aureus, устойчивый к метициллину и большинству других β-лактамных антибиотиков, таких как пенициллин.Штаммы MRSA изменяют белки, связывающие пенициллин (PBP), на которые нацелены большинство β-лактамов.В штаммах MRSA эта устойчивость развивается из-за наличия гена meCA , который кодирует изменённый пенициллин связывающий белок, известный как PBP2a.Этот изменённый PBP2a обладает низкой аффинностью связывания с бета-лактамными антибиотиками, что позволяет MRSA синтезировать свою клеточную стенку даже в присутствии этих препаратов.Во многих штаммах MRSA регуляторные гены mecI и mecR1 , контролирующие экспрессию mecA , нефункциональны.Это приводит к непрерывной экспрессии PBP2a и развитию стабильного сопротивления.MRSA может проявлять гетерогенную резистентность, когда только часть бактериальной популяции проявляет резистентность, или однородную резистентность, при которой вся популяция устойчива.

Механизм устойчивости к антибиотикам при mrsa

Mechanism of Antibiotic Resistance in MRSA

Антибиотикорезистентность у бактерий возникает, когда микроорганизмы развивают способность выдерживать препараты, предназначенные для их уничтожения или подавления роста, что делает некогда эффективные методы лечения бесполезными. Это явление, вызванное генетическими изменениями и отбором под воздействием антибиотиков, представляет серьёзную угрозу для современной медицины. Механизмы включают ферменты, инактивирующие препараты (например, β-лактамазы), насосы для выброса антибиотиков, мутации, изменяющие мишени антибиотиков, снижение поглощения лекарств и приобретение генов устойчивости через горизонтальный перенос генов. Резистентность может развиваться заново через мутацию или быстро распространяться через подвижные генетические элементы, такие как плазмиды и транспозоны. Селективное давление из-за неправильного и чрезмерного применения антибиотиков ускоряет появление и распространение устойчивых штаммов.Клинически инфекции, устойчивые к антибиотикам, сложнее лечить, часто требуют более токсичных или дорогих препаратов, затягивают пребывание в больнице, увеличивают расходы на здравоохранение и увеличивают заболеваемость и смертность. Глобальные оценки предупреждают о миллионах смертей ежегодно, если тенденция сопротивления продолжится.Метициллин-резистентный золотистый стафилокок (MRSA) MRSA — это парадигма устойчивости к антибиотикам. Получая ген mecA через элемент SCCmec, S. aureus производит изменённый пеницилл-связывающий белок PBP2a, который не связывается с β-лактамными препаратами, обеспечивая широкую устойчивость к пенициллинам, цефалоспоринам и карбапенемам. MRSA появился в больницах (HA-MRSA), а позже и в сообществах (CA-MRSA), вызванный как мутациями, так и горизонтальным переносом генов. Клинически MRSA вызывает тяжёлые кожные, мягкотканные, кровоточечные и пневмонические инфекции, часто лечащиеся ванкомицином, даптомицином или линезолидом, хотя у этих альтернатив есть свои ограничения.Некоторые другие примеры устойчивости к антибиотикам у бактерий:Энтерококки, устойчивые к ванкомицину (VRE) и VRSA Энтерококки, устойчивые к ванкомицину, возникли путём приобретения вангенных оперонов (например, vanA). Эти гены далее перешли в S. aureus, что привело к появлению редких, но опасных устойчивых к ванкомицину штаммы S. aureus (VRSA). Инфекции VRSA трудно лечить из-за ограниченного количества альтернатив и вызывают серьёзную клиническую проблему, несмотря на свою редкость.Лекарственно-устойчивый стрептококк пневмония (DRSP) S. pneumoniae развила устойчивость к пенициллину благодаря мутациям в белках, связывающихся с пенициллином, и к макролидам через гены метилтрансферазы. Эти изменения снизили эффективность лечения пневмонии, менингита и среднего отита, что потребовало применения антибиотиков более высокого класса, таких как цефалоспорины или фторхинолоны, которые несут свои риски.В заключение, устойчивость к антибиотикам эволюционирует через генетическую адаптацию и обмен генами, что оказывает значительное клиническое влияние на ключевые патогены, такие как MRSA, VRE/VRSA и DRSP. Обеспечение надлежащего использования антибиотиков, мониторинг резистентности, контроль инфекций и разработка новых терапевтических средств остаются необходимыми для смягчения растущего кризиса общественного здравоохранения.

Механизм устойчивости к антибиотикам при MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, ...

https://cloudfront.jove.com/files/ftp_upload/40835/40835_article_thumb_40835.jpg

mechanism-of-antibiotic-resistance-in-mrsa

Education

JoVE Core

Microbiology

Микробиология

Unit

Единица

Antimicrobial Agents

Антимикробные препараты

KEY TERMS AND CONCEPTS

ОСНОВНЫЕ ТЕРМИНЫ И ПОНЯТИЯ

how bacteria outsmart antibiotics

Antibiotic resistance in bacteria happens when microbes evolve the ability to survive drugs that once killed them or slowed their growth. Genetic change and antibiotic exposure drive this process. Over time, useful treatments can stop working.

Bacteria can resist antibiotics in several ways. Some make drug-inactivating enzymes, such as beta-lactamases. Others use efflux pumps to push antibiotics out of the cell. Resistance can also come from mutations that change the drug target, from lower drug uptake, or from new resistance genes gained through horizontal gene transfer, which is the movement of DNA between organisms.

Resistance may appear through new mutations or spread quickly through mobile genetic elements like plasmids and transposons. Misuse and overuse of antibiotics increase selection pressure, which helps resistant strains survive and spread. This makes antibiotic-resistant infections harder to treat and often forces doctors to use more toxic or more expensive drugs. These infections can also lead to longer hospital stays, higher healthcare costs, and more illness and death.

MRSA, short for methicillin-resistant Staphylococcus aureus, is a well-known example of this process. It acquired the mecA gene through the SCCmec element and makes an altered penicillin-binding protein called PBP2a. Because PBP2a does not bind beta-lactam drugs well, MRSA resists penicillins, cephalosporins, and carbapenems. MRSA first spread in hospitals as HA-MRSA and later in communities as CA-MRSA. It can cause skin, soft-tissue, bloodstream, and pneumonia infections, and it is often treated with vancomycin, daptomycin, or linezolid, although these options have limits.

Other resistant bacteria show the same problem in different forms. Vancomycin-resistant enterococci can gain van genes, such as vanA, and those genes can transfer to S. aureus to create rare but dangerous VRSA strains. Streptococcus pneumoniae can become resistant to penicillin through changes in penicillin-binding proteins and to macrolides through methyltransferase genes. These changes can make pneumonia, meningitis, and otitis media harder to treat and may require higher-tier antibiotics such as cephalosporins or fluoroquinolones.

Antibiotic resistance grows through genetic adaptation and gene exchange. Its impact reaches major pathogens such as MRSA, VRE, VRSA, and drug-resistant S. pneumoniae. Careful antibiotic use, resistance surveillance, infection control, and new treatments are important ways to slow this public health threat.

How Bacteria Outsmart Antibiotics

inhibitors of gram-positive cell wall synthesis

inhibitors-of-gram-positive-cell-wall-synthesis

How Antibiotics Block Bacterial Cell Walls

Bacterial cell walls are rigid structures built mainly from peptidoglycan. This mesh-like polymer gives bacteria strength and helps maintain cell shape. Because peptidoglycan synthesis is essential for growth, it is a major target for antibiotics. Beta-lactam antibiotics, such as penicillin, stop peptidoglycan synthesis in actively growing cells. They have a four-membered beta-lactam ring that mimics the D-alanyl-D-alanine dipeptide, which is the natural substrate for transpeptidase, also...

inhibitors of bacterial protein synthesis

inhibitors-of-bacterial-protein-synthesis

Aminoglycosides: How They Stop Bacteria

Aminoglycosides are bactericidal antibiotics that stop bacteria by targeting the ribosome and disrupting protein synthesis. They are highly potent drugs made of amino-modified sugars linked by glycosidic bonds to an aminocyclitol core, such as 2-deoxystreptamine or streptamine. Their strong positive charge helps them bind tightly to the negatively charged phosphate backbone of ribosomal RNA, especially the 16S rRNA of the 30S subunit in the bacterial 70S ribosome. These antibiotics act at the...

inhibitors of bacterial dna synthesis

Fluoroquinolone Antibiotics and Bacterial DNA

Fluoroquinolone antibiotics target bacterial DNA replication by blocking two key type II topoisomerases: DNA gyrase and topoisomerase IV. These enzymes help bacteria manage DNA supercoiling and separate chromosomes during replication. When they are disrupted, bacterial pathogens cannot copy DNA efficiently and infection can spread less effectively. Fluoroquinolones are synthetic versions of quinolones. They work by stabilizing the short-lived DNA-enzyme cleavage complex, which stops strand...

inhibitors of viral protein synthesis

Interferons Block Viral Replication

Interferons block viral replication by shutting down protein synthesis and activating the cell’s antiviral defenses. Viruses need the host cell’s translational machinery to make proteins, because they do not have the machinery to do this on their own. When a virus is detected, infected cells release interferons, which are cytokines, or signaling proteins, that warn nearby uninfected cells. Interferons bind to receptors on nearby cells and activate the JAK-STAT signaling pathway. This turns on...

inhibitors of virion release

Neuraminidase Inhibitors and Flu Spread

Influenza viruses spread when new virions leave an infected cell and reach nearby cells. Influenza A and B are negative-sense, single-stranded RNA viruses with segmented genomes. They depend on two surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA), to infect cells, make new viral particles, and release them. HA starts infection by binding to sialic acid on the surface of host epithelial cells. This binding helps the virus enter the cell by receptor-mediated endocytosis. After...

antiviral nucleoside inhibitors

How Antiviral Drugs Stop Viral Replication

Antiviral nucleoside inhibitors stop viruses by blocking DNA or RNA synthesis. These drugs are structural analogs, which means they look like natural nucleosides, the building blocks cells use to make genetic material. Because they resemble host nucleosides, they can interfere with viral polymerases and disrupt viral genome replication. Acyclovir is a guanosine analog with a three-carbon acyclic side chain. It mainly targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2...

antifungal agents

Amphotericin B and Fungal Membranes

Amphotericin B targets fungal cell membranes by binding to ergosterol, a sterol found mainly in fungal plasma membranes. Its amphipathic structure helps this selective binding. It has a hydrophobic polyene-lactone ring and a hydrophilic region with mycosamine and carboxylic acid groups. Weak binding to cholesterol can also affect human cells and helps explain the drug’s toxicity. One way amphotericin B kills fungi is through pore formation. In this model, amphotericin B-ergosterol complexes...

mechanism of antibiotic resistance in mrsa

Antibiotic resistance in bacteria happens when microbes evolve the ability to survive drugs that once killed them or slowed their growth. Genetic change and antibiotic exposure drive this process. Over time, useful treatments can stop working. Bacteria can resist antibiotics in several ways. Some make drug-inactivating enzymes, such as beta-lactamases. Others use efflux pumps to push antibiotics out of the cell. Resistance can also come from mutations that change the drug target, from lower...

anthelminthic agents

Helminth Drugs and How They Work

Helminth drugs work by attacking the weak points of parasitic worms. These anthelmintic medicines are different from drugs used against protozoa, because they are usually aimed at mature helminths rather than fast-dividing cells. They target the worm’s movement, glucose use, and microtubule structure to stop survival, reproduction, and location inside the host. Benzimidazoles are broad-spectrum anthelmintics that block tubulin polymerization, which means they interfere with microtubules, the...

clinical significance of antibiotic resistance

clinical-significance-of-antibiotic-resistance

MRSA: Host Adaptation and Transmission

MRSA, or methicillin-resistant Staphylococcus aureus, is a major public health threat. It resists beta-lactam antibiotics because it carries the mecA gene inside the staphylococcal cassette chromosome mec, or SCCmec. The mecA gene makes penicillin-binding protein 2a, which reduces how well methicillin and related beta-lactam drugs can bind. MRSA has spread into separate clonal lineages that affect both humans and animals. These lineages fit the One Health idea, which links human, animal, and...

inhibitors of virion maturation and assembly

inhibitors-of-virion-maturation-and-assembly

HIV Protease Inhibitors and Maturation

HIV protease inhibitors block a key step in virus maturation. In human immunodeficiency virus (HIV), infected cells make two long precursor proteins called polyproteins. These are Gag and Gag-Pol. Gag provides the virus structure. Gag-Pol carries important viral enzymes, including reverse transcriptase, integrase, and protease. After these polyproteins are made, they move to the host cell membrane. There, they help build an immature viral particle that buds from the cell surface. Budding...

antiprotozoal agents

Leishmaniasis and Trypanothione Reductase

Leishmaniasis is a parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. Treatment often relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. The way these drugs work has not been fully clear. One important target is trypanothione reductase, or TR, an enzyme that helps keep Leishmania in redox balance. TR is not found in mammalian hosts, so it is a...

key terms and concepts

Learn how bacteria become antibiotic resistant, from beta-lactamases and efflux pumps to MRSA, VRE, VRSA, and drug-resistant Streptococcus pneumoniae.

How Bacteria Outsmart Antibiotics | JoVE K12

JoVE Core Microbiology provides an engaging introduction to the microbial world and its influence on health, industry, and the environment. This comprehensive collection covers key concepts such as microbial structure, metabolism, genetics, and ecology. It introduces essential laboratory techniques and microscopy methods through visually engaging animations. Corresponding scientist-in-action videos bridge classroom concepts with real-world research and applications.

microbiology

How Bacteria Outsmart Antibiotics

Description

Transcript

Tags